SION Filings — Sionna Therapeutics, Inc. - FilingSpy
SION
Sionna Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing small-molecule drugs for cystic fibrosis, a genetic lung disease. Its lead candidates SION-719 and SION-451 target a genetic defect found in about nine in ten people with the condition, aiming to complement the standard therapy Trikafta. Founded in 2019 by two scientists building on decades of CFTR research, the company began life as Sling Therapeutics before renaming itself Sionna in 2021.
Sionna's net loss widened to $29.9M as R&D spending climbed ahead of pivotal mid-2026 data readouts.
The accelerated to its highest level yet. The net loss widened to $29.9 million from $18.1 million a year ago, driven by a $6.5 million increase in R&D expenses for NBD1 stabilizer trials, while cash and marketable securities fell to $268.3 million. The company's future hinges entirely on the Phase 2a and Phase 1 data expected this summer.
Key takeaways
Research and development expenses rose to $21.9 million, a $6.5 million increase from the same quarter last year, which management attributed to heightened clinical activity for the NBD1 stabilizer and combination programs.
General and administrative expenses increased $4.1 million to $10.6 million, primarily from a $4.0 million rise in personnel-related costs including .
The net loss of $29.9 million was the largest quarterly loss reported, up from $26.8 million in the prior quarter, as operating expense growth outpaced interest income.
Cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026, down from $289.9 million at the end of the first quarter, with management reiterating the runway extends into 2028.
The company has not yet sold any shares under the $250 million established in March 2026.
What changed
The mid-2026 data readouts flagged in every prior filing are now imminent, described in this quarter's risk factors as expected in 'summer 2026,' with no indication of delay.
The quarterly reached $22.2 million in operating cash outflow, the highest level reported, up from $18.2 million in the same quarter last year and $21.8 million in the prior quarter, as clinical activity ramps toward the data readouts.
Interest income fell $1.1 million to $2.6 million, a reversal from prior quarters where rising rates and higher balances had boosted this line, now reflecting the declining cash position.
What to watch
Topline data from the Phase 2a PreciSION CF trial of SION-719 and the Phase 1 dual combination trial of SION-451, both expected in summer 2026.
Whether the company begins selling shares under the $250 million at-the-market equity program, which would signal a need to supplement the $268.3 million cash position.
Any disclosure on the impact of the BIOSECURE Act and the status of replacing the Chinese CDMO, which could affect clinical trial timelines and costs.
Section summaries
Management's Discussion and Analysis
Net loss widened to $29.9M in Q2 2026 on higher R&D and G&A spend, with $268.3M cash expected to fund operations into 2028.
⌄
R&D expenses rose $6.5M to $21.9M in Q2 2026, driven by increased clinical activity for NBD1 stabilizers and combination programs and higher personnel costs.
G&A expenses increased $4.1M to $10.6M in Q2 2026, primarily due to a $4.0M rise in personnel-related costs including .
Interest income fell $1.1M to $2.6M in Q2 2026, reflecting lower average cash and marketable securities balances used to fund operations.
A new risk factor cites the BIOSECURE Act, which may force the company to replace a Chinese CDMO manufacturing clinical materials, introducing a potential supply chain disruption not mentioned in earlier filings.
The quarterly cash consumption rate relative to the $268.3 million balance, to confirm the runway into 2028 remains intact as spending peaks around the data readouts.
Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026, with no shares yet sold under the $250M at-the-market equity program established in March 2026.
Management expects existing cash to fund operations into 2028, but will need substantial additional capital to advance clinical development and pursue regulatory approvals.
Quantitative and Qualitative Disclosures About Market Risk
As a "smaller reporting company," as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K, we are not required to provide quantitative and qualitative disclosures about market risk.
⌄
As a "smaller reporting company," as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K, we are not required to provide quantitative and qualitative disclosures about market risk.
From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by u…
⌄
From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. Our management is currently not aware of any legal matters that could have a material effect on our financial position, results of operations or cash flows.
Clinical-stage CF biotech with no approved products faces substantial doubt about funding, development success, and competition from entrenched standard of care.
⌄
The company is substantially dependent on advancing at least one NBD1 stabilizer (SION-719 or SION-451) into later-stage trials, with key Phase 2a and Phase 1 data expected in summer 2026.
Developing a novel NBD1-targeting therapy, either as an add-on to standard of care or a proprietary dual combination, introduces significant scientific, regulatory, and clinical risks, including demonstrating efficacy over Trikafta.
Vertex holds substantial market share in CF with approved products like Trikafta and Alyftrek, posing a major competitive threat that could limit market acceptance even if the company's candidates are approved.
The company will need substantial additional capital to fund operations beyond 2028, and its ability to raise funds may be harmed by market volatility, financing terms, or loss of rights to product candidates.
Reliance on third-party licenses from Sanofi and AbbVie is critical; losing these rights due to breach or failure to meet obligations could force the company to cease operations.
A new U.S. law (the BIOSECURE Act) may force the company to replace a Chinese CDMO that manufactures clinical materials, potentially causing costly and disruptive supply chain transitions.